What is CagriSema and why is it so effective?

CagriSema combines Cagrilintide (amylin analog) with Semaglutide (GLP-1 agonist) in a single weekly injection. This dual-pathway approach targets multiple satiety mechanisms, showing up to 25% weight loss in Phase 3 clinical trials.

How is CagriSema dosed?

CagriSema uses a gradual titration schedule, typically increasing both components every 4 weeks. The combination requires careful dose management to minimize gastrointestinal side effects while maximizing weight loss.

What advantages does CagriSema have over single agents?

CagriSema provides greater weight loss than either component alone by activating complementary satiety pathways. Clinical trials show significantly more patients achieving 20%+ weight loss compared to Semaglutide or placebo.

Is CagriSema FDA approved?

As of 2024, CagriSema is in Phase 3 clinical trials (REDEFINE program) and not yet FDA approved. It is being developed by Novo Nordisk with anticipated approval pending positive trial results.

What side effects does CagriSema cause?

Side effects are similar to other GLP-1 medications: nausea, vomiting, diarrhea, and constipation. The combination may have higher GI side effect rates initially, but these typically improve with continued use and proper titration.

Precision Tool

CagriSema Dosage Calculator

Calculate the exact injection volume for your CagriSema dose. This combination pairs a GLP-1 agonist with an amylin analog.

Input Values

Peptide Vial Size

Total peptide in your vial

Bacteriostatic Water

Amount of BAC water added

Desired Dose

Your target dose per injection

Results

Concentration

5.00 mg/mL

Volume to Inject

0.100 mL

Insulin Syringe

10.0 units

on a 100-unit (1mL) syringe

Total Doses Per Vial

20 doses

Draw to the 10.0 unit mark on your insulin syringe to get exactly 0.5mg of peptide.

Order Research Peptides for Sale

USA-Manufactured, Third Party Tested Peptides
GMP USA Manufactured
Fast Global Shipping
Dedicated Support

Use code PEPTIDEIQ for 15% off any order

Shop Now

Clinical Dosing Guidelines

Product	Indication	Starting Dose	Max Dose
CagriSema	Weight Management (Phase 3)	Titration varies	Up to 2.4mg each weekly

Titration Schedule

16+ weeks typical

Current Selection

Week 1-4 — 0.5mg

Titration schedules may vary. Always follow your clinician's guidance.

CagriSema combines Cagrilintide (amylin analog) + Semaglutide (GLP-1).

This dual-mechanism approach targets multiple satiety pathways.

Start with lower doses and escalate gradually.

Inject once weekly subcutaneously.

Clinical trials show up to 25% weight loss.

Frequently Asked Questions

See all GLP-1 medications compared

Our comprehensive reference guide covers every GLP-1 agonist — from approved blockbusters like semaglutide to next-gen candidates in clinical trials. Compare efficacy, side effects, cost, and delivery routes.

Read the Full Guide

Stay Updated

Get the latest peptide research and updates

No spam, unsubscribe anytime